

PRIOR AUTHORIZATION POLICY

POLICY: Oncology (Injectable – Programmed Death Receptor-1) – Tevimbra Prior Authorization Policy

- Tevimbra® (tislelizumab-jsgr intravenous infusion – BeiGene)

REVIEW DATE: 06/12/2024

OVERVIEW

Tevimbra, a programmed death receptor-1 (PD-1) blocking antibody, is indicated for the treatment of unresectable or metastatic esophageal squamous cell carcinoma in adults after prior systemic chemotherapy that did not include a PD-1 or programmed death-ligand 1 (PD-L1) inhibitor.¹

Guidelines

The National Comprehensive Cancer Network (NCCN) **esophageal and esophagogastric junction cancers** (version 3.2024 – April 26, 2024) clinical practice guidelines recommend Tevimbra as a “Preferred Regimen” for the treatment of unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma as a single agent, if checkpoint inhibitors were not previously used and local therapy is not indicated (category 1).^{2,3}

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Tevimbra. All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with Tevimbra as well as the monitoring required for adverse events and long-term efficacy, approval requires Tevimbra to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Tevimbra is recommended in those who meet the following criteria:

FDA-Approved Indication

- 1. Esophageal Squamous Cell Carcinoma.** Approve for 1 year if the patient meets ALL of the following (A, B, C, D, E, and F):
 - A) Patient is ≥ 18 years of age;
 - B) Patient meets ONE of the following (i or ii):
 - i. Patient has unresectable locally advanced, recurrent, or metastatic disease; OR
 - ii. Patient is not a surgical candidate; AND
 - C) Medication is used as a single agent; AND
 - D) Medication is used for subsequent therapy; AND
 - E) Patient has NOT previously received a checkpoint inhibitor; AND
Note: Examples of checkpoint inhibitors include Keytruda (pembrolizumab intravenous infusion), Opdivo (nivolumab intravenous infusion).
 - F) Medication is prescribed by or in consultation with an oncologist.

06/12/2024

© 2024. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Tevimbra is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Tevimbra intravenous infusion [prescribing information]. San Mateo, CA: BeiGene; March 2024.
2. The NCCN Drugs and Biologics Compendium. © 2024 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on June 5, 2024. Search term: tislelizumab.
3. The NCCN Esophageal and Esophagogastric Junction Cancers Clinical Practice Guidelines in Oncology (version 3.2024 – April 26, 2024). © 2024 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed June 5, 2024.